Drugs / SS-1
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01897415 | Jul 2013 → Dec 2015 | pancreatic ductal adenocarcinoma | University of Pennsylvania | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02855658 | Feb 2014 → Oct 2016 | Sjogren syndrome | China Medical University Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT02110446 | Feb 2014 → Jul 2016 | Sjogren syndrome | Chang Gung Memorial Hospital | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SS1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01897415 ↗ |
| Known as | Autologous T cells | “Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1” NCT01897415 ↗ |
| Modality | Cell therapy | “RNA CAR T cells” NCT01897415 ↗ |
| Route | Intravenous | “intravenous (IV) RNA mesothelin re-directed autologous T cell administration” NCT01897415 ↗ |